Xfund is among the backers of a $17m round for ImmuneID, which has been set up to commercialise research from Harvard University and Johns Hopkins University.
ImmuneID, a US-based precision immunology company based on Harvard University and Johns Hopkins University research, has launched with $17m in funding from investors including Harvard-aligned venture capital firm Xfund.
Longwood Fund led the round, which also included Arch Venture Partners, Pitango HealthTech and In-Q-Tel, the investment affiliate of the US intelligence community, as well as unnamed investors.
ImmuneID is working on a platform that exploits sequencing, robotic automation and artificial intelligence to identify treatments for conditions linked…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
